- Click on a protocol’s title to view its description in ClinicalTrials.gov.
- Click on (pdf) to view the protocol (WUSTL key password required).
| PI / Contact | Protocol (Sponsor) | Status |
|---|---|---|
| PI: Amir Mahmoud / Kristen Sanfilippo Contact: Kim Kramer kramerka@wustl.edu 557-747-2942 | Efgartigimod in Antiphospholipid Antibody Syndrome Patients with Elevated IgG Antibodies: A pilot feasibility trial (Washington University in St. Louis) | Not yet open to enrollment |
| PI / Contact | Protocol (Sponsor) | Status |
|---|---|---|
| PI: Elaine Majerus Contact: Sabrina Barber s.barber@wustl.edu 314-273-1440 | Atypical Hemolytic-Uremic Syndrome (aHUS) Registry (Alexion) | Open to enrollment (pdf – password protected) |
| PI / Contact | Protocol (Sponsor) | Status |
|---|---|---|
| PI: Elaine Majerus Contact: Bill Berger bergerwb@wustl.edu 314-362-9996 | CDC Community Counts: Surveillance Project for Patients with Bleeding and Blood Clotting Disorders (CDC Division of Blood Disorders) | Open |
| PI / Contact | Protocol (Sponsor) | Status |
|---|---|---|
| PI: Stephen Oh Contact: Nicole Gaudin nrgaudin@wustl.edu 314-747-7960 | A Phase 3 Study of P1101 vs Anagrelide in Essential Thrombocythemia Patients who Failed Hydroxyurea (P1101ET) (PharmaEssentia Corp) | Open to enrollment (pdf – password protected) |
| PI: Stephen Oh Contact: Nicole Gaudin nrgaudin@wustl.edu 314-747-7960 | A Phase 2b Open Label Study of Ropeginterferon (P1101) in Essential Thrombocythemia Patients (PharmaEssentia) | Pending Open (pdf – password protected) |
| PI / Contact | Protocol (Sponsor) | Status |
|---|---|---|
| PI: Elaine Majerus Contact: Rachel Cody rcody@wustl.edu 314-362-7306 | A Phase 3 Study of Valoctocogene Roxaparvovec in Hemophilia A Patients (BioMarin Pharmaceutical) | Open |
| PI: Elaine Majerus Contact: Sabrina Barber s.barber@wustl.edu 314-273-1440 | Emicizumab In Patients With Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial (Genetech) | Enrollment pending (pdf – password protected) |
| PI: Elaine Majerus Contact: Sabrina Barber s.barber@wustl.edu 314-273-1440 | Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors (Novo Nordisk Pharmaceuticals, Inc.) | Open to enrollment (pdf – password protected) |
| PI / Contact | Protocol (Sponsor) | Status |
|---|---|---|
| PI: Elaine Majerus Contact: Kim Kramer kramerka@wustl.edu 557-747-2942 | A Phase 1 Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SR604 in Participants with Hemophilia A or Hemophilia B or Factor VII deficiency (Part B only) (Equilibra Bioscience LLC) | Open to enrollment (pdf – password protected) |
| PI / Contact | Protocol (Sponsor) | Status |
|---|---|---|
| PI: Elaine Majerus Contact: Bill Berger bergerwb@wustl.edu 314-362-9996 | American Thrombosis and Hemostasis Network Data Collection (CDC Division of Blood Disorders) | Open |
| PI / Contact | Protocol (Sponsor) | Status |
|---|---|---|
| PI: Morey Blinder Contact: Kim Kramer kramerka@wustl.edu 557-747-2942 | A study to assess the tolerability of ianalumab (VAY736) with investigator’s choice thrombopoietin receptor agonist (IC TPO-RA) in patients with primary immune thrombocytopenia (ITP) (Novartis Pharmaceuticals) | Not yet open to enrollment (pdf – password protected) |
| PI / Contact | Protocol (Sponsor) | Status |
|---|---|---|
| PI: Amber Afzal Contact: Kim Kramer kramerka@wustl.edu 557-747-2942 | Pilot Study of Statins in Patients with Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS) (Washington University in St. Louis) | Closed to enrollment |
| PI / Contact | Protocol (Sponsor) | Status |
|---|---|---|
| PI: Dr. Amy Zhou Contact: Nicole Gaudin nrgaudin@wustl.edu 314-747-7960 | RSK1 Targeting in Myelofibrosis (WashU Medicine) | Enrolling (pdf – password protected) |
| PI: Stephen Oh Contact: Karyn Gordon kdgordon@wustl.edu 314-362-0156 | A Phase 3 Study of Pelabresib (CPI-0610) plus Ruxolitinib vs Placebo plus Ruxolitinib in Myelofibrosis Patients (Constellation Pharmaceuticals) | Ongoing; closed to enrollment (pdf – password protected) |
| PI: Amy Zhou Contact: Nicole Gaudin nrgaudin@wustl.edu 314-747-7960 | A Phase 1b/2a Study of DISC-0974 in Myelofibrosis Patients with Anemia (DISC-0974-102) (DISC Medicine) | Pending open (pdf – password protected) |
| PI / Contact | Protocol (Sponsor) | Status |
|---|---|---|
| PI: Elaine Majerus Contact: Sabrina Barber s.barber@wustl.edu 314-273-1440 | Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry (Alexion) | Open to enrollment |
| PI: Elaine Majerus Contact: Sabrina Barber s.barber@wustl.edu 314-273-1440 | A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb≥10 g/dL in response to anti-C5 antibody and switch to iptacopan (Novartis) | Pending enrollment (pdf – password protected) |
| PI / Contact | Protocol (Sponsor) | Status |
|---|---|---|
| PI: Stephen Oh Contact: Karyn Gordon kdgordon@wustl.edu 314-362-0156 | A Phase 2a Study of ISIS 702843 in Phlebotomy Dependent Polycythemia Vera Patients (ISIS 702843-CS4) (Ionis Pharmaceuticals) | Open to enrollment (pdf – password protected) |
| PI: Stephen Oh Contact: Karyn Gordon kdgordon@wustl.edu 314-362-0156 | A Phase 3b Study of Ropeginterferon (P1101) in Polycythemia Vera Patients (PharmaEssentia) | Pending Open (pdf – password protected) |
| PI / Contact | Protocol (Sponsor) | Status |
|---|---|---|
| PI: Stephen Oh Contact: Nicole Gaudin nrgaudin@wustl.edu 314-747-7960 | A Phase 2 Study of CGT9486 in Patients with Nonadvanced Systemic Mastocytosis (Summit) (Cogent Biosciences) | Open to enrollment (pdf – password protected) |
| PI: Stephen Oh Contact: Nicole Gaudin nrgaudin@wustl.edu 314-747-7960 | A Phase 2 Study of Avapritinib (BLU-285) in Nonadvanced Systemic Mastocytosis Patients with Inadequately Controlled Symptoms (BLU-285-2203) (Blueprint Medicines) | Ongoing; closed to enrollment (pdf – password protected) |
| PI / Contact | Protocol (Sponsor) | Status |
|---|---|---|
| PI: Elaine Majerus Contact: Sabrina Barber s.barber@wustl.edu 314-273-1440 | A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People with Severe Von Willebrand Disease (VWD) (American Thrombosis and Hemostasis Network (ATHN)) | Open to enrollment (pdf – password protected) |